Erratum: The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease (PLoS ONE (2015) 10:7 (e0129980) DOI:10.1371/journal.pone.0129980);The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Assi, Lakhvir K ^a   McIntyre, Natasha ^b   Fraser, Simon ^c   Harris, Scott ^c   Hutchison, Colin A ^d   McIntyre, Chris W ^b,e   Cockwell, Paul ^f,g   Taal, Maarten W ^b,e  

^a Binding Site Group Ltd   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Hawke's Bay District Health Board   (New Zealand)

^e ROYAL DERBY HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BICARBONATE; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; POLYCLONAL IMMUNOGLOBULIN FREE LIGHT CHAIN; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; UREA; URIC ACID; BIOLOGICAL MARKER; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICROALBUMINURIA; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; STAGING; SURVIVAL; SURVIVAL RATE; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84938841387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141404     Document Type: Erratum

References (39)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-305. PMID: 15385656
2. Matsushita K, van d V, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-81. doi: 10.1016/S0140-6736(10)60674-5 PMID: 20483451
3. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 2007; 20:566-9. PMID: 17991206
4. Tangri N, Inker L, Levey AS. A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods. J Clin Epidemiol 2013; 66:697.
5. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010; 77:550-6. doi: 10.1038/ki.2009.503 PMID: 20016471
6. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68:237-45. PMID: 15954913
7. Solomon A. Light chains of human immunoglobulins. Methods Enzymol 1985; 116:101-21. PMID: 3937021
8. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972; 51:2162-74. PMID: 5054468
9. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1684-90. doi: 10.2215/CJN.02290508 PMID: 18945993
10. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int 2011; 79:1289-301. doi: 10.1038/ki.2011.94 PMID: 21490587
11. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 2011; 57:1387-9. doi: 10.1373/clinchem.2011.169433 PMID: 21836076
12. Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep 2013; 5:4. doi: 10.3410/M5-4 PMID: 23413370
13. Anandram S, Assi LK, Lovatt T, Parkes J, Taylor J, MacWhannell A et al. Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. J Clin Pathol 2012; 65:1036-42. doi: 10.1136/jclinpath-2012-200910 PMID: 22923765
14. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 2012; 87:517-23. doi: 10.1016/j.mayocp.2012.03.009 PMID: 22677072
15. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28:773-9. doi: 10.1200/JCO.2009.25.1322 PMID: 20048176
16. Haynes R, Hutchison CA, Emberson J, Dasgupta T, Wheeler DC, Townend JN et al. Serum Free Light Chains and the Risk of ESRD and Death in CKD. Clin J Am Soc Nephrol 2011; 6:2829-37. doi: 10.2215/CJN.03350411 PMID: 22034503
17. Hutchison CA, Burmeister A, Harding SJ, Basnayake K, Church H, Jesky MD et al. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease. Mayo Clin Proc 2014; 89:615-22. doi: 10.1016/j.mayocp.2014.01.028 PMID: 24797643
18. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 2010; 5:51-5. doi: 10.2215/CJN.05350709 PMID: 19965551
19. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Risk profile in chronic kidney disease stage 3: older versus younger patients. Nephron Clin Pract 2011; 119:c269-c276.
20. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011; 6:2356-63. doi: 10.2215/CJN.02420311 PMID: 21885790
21. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437-44. PMID: 12194920
22. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47:673-80. PMID: 11274017
23. Bradwell AR. Serum free light chain analysis (plus Hevylite). 2010.
24. Astor BC, Matsushita K, Gansevoort RT, van d V, Woodward M, Levey AS et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79:1331-40. doi:10.1038/ki.2010.550 PMID: 21289598
25. Drawz PE, Baraniuk S, Davis BR, Brown CD, Colon PJ Sr., Cujyet AB et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012; 164:925-31. doi: 10.1016/j.ahj.2012.09.003 PMID: 23194494
26. U.S.Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End- Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2012.
27. Solling K. Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 1981; 157:1-83. PMID: 6797039
28. Burmeister A, Assi LK, Ferro CJ, Hughes RG, Barnett AH, Bellary S et al. The relationship between high-sensitivity CRP and polyclonal Free Light Chains as markers of inflammation in chronic disease. Int J Lab Hematol 2013.
29. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007; 122:146-55. PMID: 17046328
30. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348-54. PMID: 15257706
31. Chiche L, Cournac JM, Mancini J, Bardin N, Thomas G, Jean R et al. Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 2011; 30:685-9. doi: 10.1007/s10067-010-1674-1 PMID: 21221683
32. Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010; 69:2137-44. doi: 10.1136/ard.2009.126441 PMID: 20679475
33. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res 2011; 63:891-8.
34. Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G et al. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 2012.
35. Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009; 68:89-93. doi: 10.1136/ard.2007.086488 PMID: 18375535
36. Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009; 114:4928-32. doi: 10.1182/blood-2009-08-237651 PMID: 19828698
37. Cohen G, Rudnicki M, Horl WH. Uraemic toxins modulate the spontaneous apoptotic cell death and essential function of neutrophils. Kidney Int 2001; 59:S48-S52.
38. Redegeld FA, van der Heijden MW, Kool M, Heijdra BM, Garssen J, Kraneveld AD et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002; 8:694-701. PMID: 12068287
39. Lusignan S, Gallagher H, Jones S, Chan T, Van VJ, Tahir A et al. Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int 2013; 84:609-20. doi: 10.1038/ki.2013.96 PMID: 23536132